May 9, 2019 10:48 AM EDT
News Briefing

Gilead says on­ly Te­va can mar­ket Tru­va­da gener­ic; Den­ver nar­row­ly votes to de­crim­i­nal­ize "mag­ic mush­rooms"

Natalie Grover

Reporter

→ Un­der fire for its pric­ing pol­i­cy on its HIV pre­ven­tion pill Tru­va­da, Gilead $GILD has agreed to al­low one gener­ic drug­mak­er Te­va …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

Up­dat­ed: J&J to buy In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

A service from the Financial Times